The Clinical Outcome of Chemotherapy-Induced Amenorrhea in Premenopausal Young Patients with Breast Cancer with Long-Term Follow-up

[1]  M. Friedlander,et al.  Breast cancer in young women and its impact on reproductive function , 2009, Human reproduction update.

[2]  I. Smith,et al.  Controversies in the management of patients with breast cancer: adjuvant endocrine therapy in premenopausal women. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  W. Han,et al.  Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea--a report from the Korean Breast Cancer Society. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J Cuzick,et al.  Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials , 2007, The Lancet.

[5]  R. Elledge,et al.  The Rates of Chemotherapy-Induced Amenorrhea in Patients Treated With Adjuvant Doxorubicin and Cyclophosphamide Followed by a Taxane , 2007, American journal of clinical oncology.

[6]  S. Swain,et al.  Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  E. Winer,et al.  Menopausal-type symptoms in young breast cancer survivors. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  Farin Kamangar,et al.  Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Gelber,et al.  Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  C. Hudis,et al.  Incidence of chemotherapy‐induced, long‐term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane , 2005, Cancer.

[11]  W. Parulekar,et al.  Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study--NCIC CTG MA.5. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Bonneterre,et al.  Chemotherapy-induced amenorrhea: influence on disease-free survival and overall survival in receptor-positive premenopausal early breast cancer patients. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[14]  S. Cosimo,et al.  Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  E. Perez,et al.  Tailored treatment investigations for premenopausal women with endocrine responsive (ER+ and/or PGR+) breast cancer: The SOFT, TEXT, and PERCHE trials , 2003 .

[16]  M. Cobleigh,et al.  Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  B. Asselain,et al.  Age as prognostic factor in premenopausal breast carcinoma , 1993, The Lancet.

[18]  R. Schilsky,et al.  Prospects for fertility after cancer chemotherapy. , 1992, Seminars in oncology.

[19]  H. Mouridsen,et al.  Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  V. Jordan,et al.  Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer. , 1987, Cancer research.

[21]  D. Rose,et al.  Effects of adjuvant chemohormonal therapy on the ovarian and adrenal function of breast cancer patients. , 1980, Cancer research.

[22]  Johnstone Fr,et al.  Carcinoma of the breast in women 30 years of age or less. , 1973 .

[23]  J. Costantino,et al.  Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial , 2008, Breast Cancer Research and Treatment.

[24]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[25]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003, National Cancer Institute. Bethesda, MD, , 2006 .

[26]  青儀 健二郎,et al.  What's going on 乳癌 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group(EBCTCG). Lancet. 2005; 365: 1687-717. PMID: 15894097.--早期乳癌に対する化学療法・内分泌療法が乳癌再発・15年生存率に及 , 2006 .

[27]  J. Ingle,et al.  Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients , 2004, Cancer Chemotherapy and Pharmacology.

[28]  R. Gelber,et al.  The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. The International Breast Cancer Study Group. , 1990, Annals of oncology : official journal of the European Society for Medical Oncology.